Levocetirizine is an effective treatment in patients suffering from chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled, parallel, multicenter study

International Journal of Dermatology

Volumn 45, Issue 4, 2006, Pages 469-474

  Kapp, Alexander ^a,b   Pichler, Werner J ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; LEVOCETIRIZINE; PLACEBO;

ABSENTEEISM; ADULT; ARTICLE; CHRONIC URTICARIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG APPROVAL; DRUG EFFICACY; ERYTHEMA; FATIGUE; FEMALE; HEADACHE; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRODUCTIVITY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN MANIFESTATION; URTICARIA;

ADULT; CETIRIZINE; CHRONIC DISEASE; DOUBLE-BLIND METHOD; EFFICIENCY; FEMALE; GERMANY; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; PIPERAZINES; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SICK LEAVE; SWITZERLAND; URTICARIA;

EID: 33645549364     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2005.02609.x     Document Type: Article

References (20)

1. Greaves MW. Chronic idiopathic urticaria. Curr Opin Allergy Clin Immunol 2003; 3: 363-368.
2. Black AK, Greaves MW. Antihistamines in urticaria and angioedema. Clin Allergy Immunol 2002; 17: 249-286.
3. Simons FE. Comparative pharmacology of H1 antihistamines: Clinical relevance. Am J Med 2002; 113: 38S-46S.
4. Gillard M, Van Der Perren C, Moguilevsky N, et al. Binding characteristics of cetirizine and levocetirizine to human H(1) histamine receptors: Contribution of Lys(191) and Thr(194). Mol Pharmacol 2002; 61: 391-399.
5. Devalia JL, De Vos C, Hanotte F, et al. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. Allergy 2001; 56: 50-57.
6. Zuberbier T, Greaves MW, Juhlin L, et al. Definition, classification, and routine diagnosis of urticaria: A consensus report. J Invest Dermatol Symp Proc 2001; 6: 123-127.
7. Zuberbier T. Urticaria. Allergy 2003; 58: 1224-1234.
8. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.
9. Lewis V, Finlay AY. 10 years experience of the Dermatology Life Quality Index (DLQI). J Invest Dermatol Symp Proc 2004; 9: 169-180.
10. Barber JA, Thompson SG. Analysis of cost data in randomized trials: An application of the non-parametric bootstrap. Stat Med 2000; 19: 3219-3236.
11. Finlay AY, Coles EC. The effect of severe psoriasis on the quality of life of 369 patients. Br J Dermatol 1995; 132: 236-244.
12. Kiebert G, Sorensen SV, Revicki D, et al. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol 2002; 41: 151-158.
13. Williamson D, Gonzalez M, Finlay AY. The effect of hair loss on quality of life. J Eur Acad Dermatol Venereol 2000; 15: 137-139.
14. Zuberbier T, Greaves MW, Juhlin L, et al. Management of urticaria: A consensus report. J Invest Dermatol Symp Proc 2001; 6: 128-131.
15. Thompson AK, Finn AF, Schoenwetter WF. Effect of 60 mg twice-daily fexofenadine HCl on quality of life, work and classroom productivity, and regular activity, in patients with chronic idiopathic urticaria. J Am Acad Dermatol 2000; 43: 24-30.
16. Ring J, Hein R, Gauger A, et al. Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: A randomized, double-blind, placebo-controlled study. Int J Dermatol 2001; 40: 72-76.
17. Clough GF, Boutsiouki P, Church MK. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. Allergy 2001; 56: 985-988.
18. Grant JA, Riethuisen JM, Moulaert B, et al. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: Suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. Ann Allergy Asthma Immunol 2002; 88: 190-197.
19. Denham KJ, Boutsiouki P, Clough GF, et al. Comparison of the effects of desloratadine and levocetirizine on histamine-induced wheal, flare and itch in human skin. Inflamm Res 2003; 52: 424-427.
20. Purohit A, Melac M, Pauli G, et al. Twenty-four-hour activity and consistency of activity of levocetirizine and desloratadine in the skin. Br J Clin Pharmacol 2003; 56: 388-394.